Health & Environmental Research Online (HERO)


Print Feedback Export to File
2744685 
Journal Article 
Etizolam: controlled study versus alprazolam in the treatment of generalized anxiety disorder with minor associated depressive symptoms 
Bramanti, P; Ricci, RM; Rifici, C; Di Perri, R; Et al 
1990 
Yes 
Current Therapeutic Research
ISSN: 0011-393X 
IPA/91/938075 
Ther 
REF 22 
369-377 
English 
IPA COPYRIGHT: ASHP A single blind study was conducted to compare the efficacy and safety of etizolam with those of alprazolam in 24 female patients (aged 27-56 yr) with generalized anxiety disorder who received an oral tablet of 0.5 mg etizolam or alprazolam twice daily for 5 wk. Etizolam had a therapeutic effect comparable to that of alprazolam. However, the etizolam group had a significantly more marked reduction of the symptoms amenable to somatization of anxiety, including cardiovascular, gastrointestinal and neurovegetative symptoms. Both drugs were well tolerated. Eighty-five percent of the alprazolam group and 54.5% of the etizolam group required a dosage increase to 0.5 mg 3 times daily. It was concluded that etizolam was more effective than alprazolam against the symptoms of somatization of anxiety, with fewer patients requiring an increase in the daily dosage.